CURIS Share Price | Curis Lifesciences Ltd Stock Analysis & Recommendation

Q: What does Curis Lifescien. do?

Overview: Curis Lifesciences Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.History: Curis Lifesciences Ltd was incorporated as a Private Limited Company in 2016, having transitioned from its original status as a Partnership Firm established in 2010. The most recent quarterly results reported net sales and net profit for June 2025.Financial Snapshot: Most recent Net Sales: 20 Cr (Quarterly Results - Jun 2025) Most recent Net Profit: 3 Cr (Quarterly Results - Jun 2025) Market-cap value: INR 86 Cr (Micro Cap)Key Metrics: P/E: 13.00 Industry P/E: 34 Dividend Yield: 0.00% Debt-Equity: 0.39 Return on Equity: 14.63% Price to Book: 1.88 Contact Details: Registrar Address: Not available. Phone: N/A Email: N/A Website: N/A

Q: How big is Curis Lifescien.?

As of 10th June, Market Cap: Curis Lifesciences Ltd has a market capitalization of 86.00 Cr, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest quarter ending in June 2024, the company reported Net Sales of 9.12 Cr and a Net Profit of 1.20 Cr.Balance Sheet Snapshot: As of March 2025, the Shareholder's Funds amounted to 16.23 Cr, while the Total Assets were valued at 42.53 Cr.

Q: Who are the peers of the Curis Lifescien.?

Peers: The peers of Curis Lifescien. are Vaishali Pharma, Onyx Biotec, Mercury Labs, Makers Labs., Amwill Health, Pharmaids Pharma, Denis Chem Lab, Bharat Immunolog, Concord Drugs, Bacil Pharma.Quality Snapshot: Excellent management risk is observed at Mercury Labs, Amwill Health, and Denis Chem Lab, while Average management risk is found at Onyx Biotec and the rest have Below Average management risk. Growth is rated as Excellent for Amwill Health and Denis Chem Lab, Average for Onyx Biotec, and Below Average for the rest. In terms of Capital Structure, Excellent ratings are given to Mercury Labs, Amwill Health, and Denis Chem Lab, while Average is observed at Onyx Biotec, and the rest have Below Average ratings.Return Snapshot: The peer with the highest 1-year return is Onyx Biotec at -20.00%, while the peer with the lowest is Vaishali Pharma at -42.53%. Curis Lifescien.'s 1-year return is not available for comparison. Additionally, Vaishali Pharma and Bharat Immunolog have negative six-month returns.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

5.0 k (-59.68%) Volume

Shareholding (Mar 2026)

FII

1.19%

Held by 3 FIIs

DII

5.80%

Held by 0 DIIs

Promoter

68.03%

Why is Curis Lifesciences Ltd falling/rising?

19-Jul-2026

As of 18-Jul, Curis Lifesciences Ltd's stock price is rising to 109.00, up 3.76%. This increase is driven by strong relative performance, heightened investor participation, and positive trading momentum, despite a year-to-date decline.

View full answer

Which are the latest news on Curis Lifescien.?

19-Jul-2026

No latest news for Curis Lifescien. found.

What does Curis Lifescien. do?

11-Jun-2026

Curis Lifesciences Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, incorporated in 2016, with recent net sales of 20 Cr and net profit of 3 Cr as of June 2025. Key metrics include a P/E of 13.00 and a market cap of INR 86 Cr.

View full answer

How big is Curis Lifescien.?

11-Jun-2026

As of 10th June, Curis Lifesciences Ltd has a market capitalization of 86.00 Cr, with recent net sales of 9.12 Cr and a net profit of 1.20 Cr for the latest quarter.

View full answer

Who are the peers of the Curis Lifescien.?

11-Jun-2026

Curis Lifescien.'s peers include Vaishali Pharma, Onyx Biotec, Mercury Labs, and others, with varying management and growth risks. Onyx Biotec has the highest 1-year return at -20.00%, while Vaishali Pharma has the lowest at -42.53%.

View full answer

Compare Curis Lifescien. with Similar Stocks

Makers Labs.Amwill Health Zenith Drugs

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 84 Cr (Micro Cap)

P/E

13.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.39

Return on Equity

14.63%

Price to Book

1.79

Revenue and Profits:

Net Sales:

20 Cr

(Quarterly Results - Jun 2025)

Net Profit:

3 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-2.77%

6 Months

-11.67%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Curis Lifescien. for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

6.98

Debt to EBITDA (avg)

1.59

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

1.29

Tax Ratio

27.72%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.99%

ROCE (avg)

25.36%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.86

EV to EBIT

10.21

EV to EBITDA

9.57

EV to Capital Employed

1.62

EV to Sales

1.76

PEG Ratio

Dividend Yield

ROCE (Latest)

15.86%

ROE (Latest)

14.63%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Sideways

KST

Dow Theory

Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 3 FIIs (1.19%)

Promoter with highest holding

Pawasia Siddhant J (19.05%)

Highest Public shareholder

SS Corporate Securities Limited (2.81%)

Individual Investors Holdings

14.38%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19.50",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.23",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.29",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "2.87",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.69%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is -18.77% vs 116.10% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 5.25% vs 81.82% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "27.91",
          "val2": "34.36",
          "chgp": "-18.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.99",
          "val2": "6.93",
          "chgp": "-13.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.43",
          "val2": "0.61",
          "chgp": "-29.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.04",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "4.21",
          "val2": "4.00",
          "chgp": "5.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.46%",
          "val2": "20.17%",
          "chgp": "1.29%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "47.41",
          "val2": "35.40",
          "chgp": "33.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "10.22",
          "val2": "8.05",
          "chgp": "26.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.72",
          "val2": "0.79",
          "chgp": "-8.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.02",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "7.08",
          "val2": "5.07",
          "chgp": "39.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.56%",
          "val2": "22.74%",
          "chgp": "-1.18%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 20.63% vs 41.34% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 11.43% vs 27.52% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "60.63",
          "val2": "50.26",
          "chgp": "20.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "11.13",
          "val2": "10.74",
          "chgp": "3.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.14",
          "val2": "1.11",
          "chgp": "2.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.01",
          "val2": "0.01",
          "chgp": "-200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "6.92",
          "val2": "6.21",
          "chgp": "11.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "18.36%",
          "val2": "21.37%",
          "chgp": "-3.01%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Jun'25 - QoQ

Jun'25

Change(%)

Net Sales

19.50

Operating Profit (PBDIT) excl Other Income

4.23

Interest

0.29

Exceptional Items

0.00

Standalone Net Profit

2.87

Operating Profit Margin (Excl OI)

21.69%

NA%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Mar'25

Change(%)

Net Sales

27.91

34.36

-18.77%

Operating Profit (PBDIT) excl Other Income

5.99

6.93

-13.56%

Interest

0.43

0.61

-29.51%

Exceptional Items

0.00

0.04

-100.00%

Standalone Net Profit

4.21

4.00

5.25%

Operating Profit Margin (Excl OI)

21.46%

20.17%

1.29%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2025 is -18.77% vs 116.10% in Mar 2025

Standalone Net Profit

Growth in half year ended Sep 2025 is 5.25% vs 81.82% in Mar 2025

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Jun'25

Jun'25

Change(%)

Net Sales

47.41

35.40

33.93%

Operating Profit (PBDIT) excl Other Income

10.22

8.05

26.96%

Interest

0.72

0.79

-8.86%

Exceptional Items

0.00

-0.02

100.00%

Standalone Net Profit

7.08

5.07

39.64%

Operating Profit Margin (Excl OI)

21.56%

22.74%

-1.18%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Standalone) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

60.63

50.26

20.63%

Operating Profit (PBDIT) excl Other Income

11.13

10.74

3.63%

Interest

1.14

1.11

2.70%

Exceptional Items

-0.01

0.01

-200.00%

Standalone Net Profit

6.92

6.21

11.43%

Operating Profit Margin (Excl OI)

18.36%

21.37%

-3.01%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 20.63% vs 41.34% in Mar 2025

Standalone Net Profit

YoY Growth in year ended Mar 2026 is 11.43% vs 27.52% in Mar 2025

All Annual Results

Company CV

About Curis Lifesciences Ltd

Curis Lifesciences Ltd

Micro Cap

Pharmaceuticals & Biotechnology

Curis Lifesciences Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name and style of "M/s Loreto Pharmaceutacals", pursuant to a Deed of Partnership dated 2 June, 2010. Thereafter " M/s Loreto Pharmaceutacals" was converted from Partnership Firm to a Private Limited Company as "Curis Lifesciences Private Limited" and received a Certificate of Incorporation dated on March 23rd, 2016 issued by Registrar of Companies, Ahmedabad.

Company Coordinates

No Company Details Available